WillItSurvive
No grouping · absorbed · United States

EvolutionaryScale

evolutionaryscale.ai ↗

AI protein design startup that built ESM3 models for biology and drug discovery.

Little protection left
Assessed 30 July 2026 · Evidence as of 30 July 2026
Not much stands between this business and its pressures.
On the recordSince 30 July 2026 · Checkable from by Q1 2027 · Every call on the record Checkpoint: Possible disclosure of Biohub acquisition terms or further wind-down of the EvolutionaryScale entity
The call

EvolutionaryScale's team and technology now live inside the nonprofit Chan Zuckerberg Biohub, ending its run as an independent company after just 16 months.

EvolutionaryScale built AI tools to predict how proteins fold and behave, work that won scientific praise and backing from top researchers. The company could not compete because rivals like Isomorphic Labs and Chai Discovery had far more money and signed deals with drug companies that EvolutionaryScale could not match. In November 2025, the entire team joined the Chan Zuckerberg Biohub nonprofit instead of staying independent, meaning the company ceased to exist as a business. The key question is whether seed investors and early employees got paid anything when they were acquired by a nonprofit, which typically signals a down outcome rather than success.

Why
01
AI pressure: Chai Discovery and Xaira Therapeutics. Better-funded rivals signed pharma deals with Lilly and Pfizer while EvolutionaryScale's team got absorbed into a nonprofit. Could AI do the core job? Yes, likely.
02
Bigger players: Isomorphic Labs (Alphabet/DeepMind). AlphaFold 3 and $2.1B in funding let Isomorphic outpace EvolutionaryScale's ESM3 in scale and pharma traction. Could a giant copy it? Yes, easily.
03
What protects it. None apparent. The company no longer operates independently.
What would change this call
Whether an independent EvolutionaryScale entity or product ever re-emerges outside Biohub. Would indicate the company retained any separate commercial path after absorption.
Whether Biohub discloses the financial terms of the November 2025 transaction. Would show whether seed investors and founders received meaningful returns.
Whether Chai Discovery, Xaira, or Isomorphic Labs announce new pharma partnerships or funding rounds in 2026. Would confirm those rivals continued pulling ahead in capital and deal traction.
Key numbers
  • Raised $142M seed round, June 2024 (2024-06-25)
  • Headcount fell from 32 to 19, mid-2026 (2026-07-06)
  • Chai Discovery valued at $3.8B, July 2026 (2026-07-01)
Named risks
  • Company ceased independent operations, absorbed into nonprofit Biohub with undisclosed transaction terms. Severity: high
  • No disclosed paying pharma customer or revenue through entire independent operating period. Severity: high
  • Vastly outraised by rivals: Isomorphic $2.1B, Chai $3.8B valuation, Xaira over $1B versus EvolutionaryScale's $142M. Severity: high
  • Headcount fell from a 32-person peak in December 2024 to 19 by June 2026. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Isomorphic Labslosing toAlphabet-backed rival reportedly raised $2.1B by May 2026 versus EvolutionaryScale's single $142M round
Chai Discoverylosing toClosed $400M Series C at $3.8B valuation July 14, 2026 with paid Lilly and Pfizer deals EvolutionaryScale never disclosed
Xaira Therapeuticslosing toRaised over $1B and shipped X-Cell virtual-cell model March 30, 2026 while EvolutionaryScale was being absorbed
AI ProteinscontestingSmaller Boston rival raised $73M Series A in November 2025, same window as EvolutionaryScale's Biohub absorption
Questions people ask
Is EvolutionaryScale still an independent company in 2026?
No. On November 6, 2025 EvolutionaryScale's roughly 50-person team joined the nonprofit Chan Zuckerberg Biohub Network in a strategic transaction with undisclosed terms. Endpoints News called it the apparent end of the startup, and by mid-2026 the standalone entity showed only 18 to 19 tracked employees.
Who owns EvolutionaryScale now?
EvolutionaryScale's team and technology were absorbed into the Chan Zuckerberg Biohub Network, a 501(c)(3) nonprofit co-founded by Mark Zuckerberg and Priscilla Chan, per a November 6, 2025 announcement. Founder Alex Rives became Biohub's Head of Science by March 2026.
Did EvolutionaryScale have layoffs before it was absorbed?
Headcount tracking shows a decline rather than a formal layoff announcement: EvolutionaryScale grew to a peak of 32 employees in December 2024, then fell to 19 by June 2026, a 57.8 percent year over year drop, per Crustdata LinkedIn tracking as of July 2026.
Who is EvolutionaryScale's biggest competitor?
Isomorphic Labs (Alphabet/DeepMind), which reportedly raised about $2.1 billion by May 2026, alongside Chai Discovery, which closed a $400 million Series C at a $3.8 billion valuation on July 14, 2026 with paid Eli Lilly and Pfizer partnerships EvolutionaryScale never disclosed.
Is EvolutionaryScale profitable?
No audited or company disclosed revenue figures exist for EvolutionaryScale. The company never publicly disclosed a paying pharma customer during its roughly 18 months of independent operation, through the November 6, 2025 absorption into the Chan Zuckerberg Biohub.
Could AI replace EvolutionaryScale?
EvolutionaryScale's entire product was itself an AI model, so it was not disrupted by AI but out-funded by AI-biology rivals. It ceased independent operations on November 6, 2025 after Isomorphic Labs, Chai Discovery, and Xaira all out-raised and out-partnered it.
Timeline
  • 2026-05-31Biohub launches fourth-generation ESM world model built on EvolutionaryScale's lineage, via biohub.ai, AWS, SandboxAQ
  • 2026-03-02Rives named Biohub Head of Science; Biohub commits to 10,000 GPUs by 2028
  • 2025-11-06EvolutionaryScale's roughly 50-person team joins Chan Zuckerberg Biohub in undisclosed-terms transaction
  • 2025-02-12ESM3 Forge API reaches public beta via NVIDIA NIM/BioNeMo
  • 2025-01-31ESM3 esmGFP research published in Science journal
  • 2024-12ESM Cambrian representation-learning model family launched
  • 2024-08-12ESM3-open (1.4B parameters) released under non-commercial license on Hugging Face
  • 2024-06-25EvolutionaryScale launches ESM3 and announces $142M seed round led by NFDG
  • 2023-07EvolutionaryScale founded by Alexander Rives, Tom Sercu, Sal Candido, ex-Meta FAIR
Revision history
30 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources